Kolon Life Science wins Canadian patent for cancer virus production

Kolon Life Science said Wednesday that it has received a notice of allowance in Canada for a patent covering the manufacturing process of KLS-3021, its oncolytic virus candidate for solid tumors, strengthening the company's intellectual property portfolio and commercialization prospects in North America.

The patent covers a large-scale production method for vaccinia-virus-based therapies using suspension-cultured HeLa S3 cells.

The technology is designed to improve manufacturing efficiency and s ...